RxDoctor Payments Data

Priyal Patel, MD

Family Medicine · New Boston, TXNPI 1205220654

Payments from drug & device makers

$326in general payments, 2019–2025

Across 23 payments — averaging $14.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$55
  • Amgen$44
  • Sanofi-aventis U.S. LLC$40
  • Amarin Pharma, Inc.$37
  • Takeda Pharmaceuticals U.S.A., Inc.$29
  • Novo Nordisk$26
  • plus $95 from 5 others

What the payments were for

  • Food & beverage$30593%
  • Education$217%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$326 in reported general payments places this provider in the 40th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$62,602
Medicare patients
172
Services billed
861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide119$128,865
EliquisApixaban108$95,291
JanuviaSitagliptin Phosphate55$57,684
FarxigaDapagliflozin Propanediol43$39,363
LinzessLinaclotide37$26,401
JardianceEmpagliflozin21$24,780
MounjaroTirzepatide19$22,006
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$13,704
Tresiba Flextouch U-100Insulin Degludec12$11,234
JanumetSitagliptin Phos/Metformin Hcl15$11,230
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$10,706
Breo ElliptaFluticasone/Vilanterol24$10,489
Humalog Kwikpen U-100Insulin Lispro29$7,393
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen312$7,248
Albuterol Sulfate HfaAlbuterol Sulfate204$7,092

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$26$128,865119 claims
PfizerEliquis$24$95,291108 claims
MerckJanuvia, Janumet$11$68,91470 claims
AstraZenecaFarxiga, Symbicort$55$42,39255 claims
AbbVieLinzess, Synthroid$23$28,57371 claims
GSKTrelegy Ellipta, Breo Ellipta$15$24,19341 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 8,760 family medicine providers in Texas.

Other family medicine in New Boston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →